UBS raised the firm’s price target on Teva to $11 from $8 and keeps a Neutral rating on the shares. Uzedy’s early launch metrics look encouraging and sales performance may surpass expectations, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TEVA: